In one study, patients with PCOS have reduced levels of α2-macroglobulin in the plasma [31], meaning that the efficacy of hepcidin to bind ferroportin and promote its degradation is compromised in PCOS patients. This evidence concerns the gene SLC40A1 and polycystic ovary syndrome.